Evidence map›Paper›PMID 36147908›Full record

ArticleFrontiers in oncology2022

Next-generation sequencing based detection of

Dingchao Hua, Qiuhong Tian, Xue Wang, Ting Bei, Lina Cui, Bei Zhang, Celimuge Bao, Yuezong Bai, Xiaochen Zhao, Peng Yuan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Dingchao HuaDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Qiuhong TianDepartment of Medical Oncology, First Affiliated Hospital of Nanchang University, Nanchang, China.
Xue WangNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ting BeiDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Lina CuiDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Bei ZhangDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Celimuge BaoDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Yuezong BaiDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, China.
Xiaochen ZhaoDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Peng YuanNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Nanchang University · CNMinistry of Education of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRCAbreast cancerlarge genomic rearrangementsnext-generation sequencingovarian cancerpan-cancer

Identifiers

PMID36147908
PMCPMC9487528
OpenAlexW4294756227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.